+ Watch AMGN
on My Watchlist
A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.
Steadily growing earnings. Excellent margins and ROE. PE is fair, but it looks like this will drop; not because the price will drop, but because the earnings are poised to rise.
While Amgen has a very enviable ROE, over the past few years, revenue growth has been modest. Amgen is actually sharing many characteristic with Telecom companies, such AT&T : high barriers to entry once, that are fading slowly but surely. Don't get surprised if share buy backs and acquisitions are the mode of operations for Amgen.Looking at the financials, Q2 and YTD revenues are declining Y/Y, and Free cash flow in Q2 was very week (down $800M Y/Y).To conclude, the ride may not be over with the biotech group, but one day, investors will realize growth might not show up, and only multiple expansion is truly leading Amgen equity.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions